A longitudinal study of CEACAM1 expression in melanoma disease progression

Zippel,Douglas; Barlev,Hani; Ortenberg,Rona; Barshack,Iris; Schachter,Jacob; Markel,Gal

doi:10.3892/or.2014.3703

A longitudinal study of CEACAM1 expression in melanoma disease progression

Authors:
- Douglas Zippel
- Hani Barlev
- Rona Ortenberg
- Iris Barshack
- Jacob Schachter
- Gal Markel
View Affiliations

Affiliations: Department of Surgery C, Chaim Sheba Medical Center, Tel Hashomer, Israel, Ella Institute of Melanoma, Chaim Sheba Medical Center, Tel Hashomer, Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Published online on: December 30, 2014 https://doi.org/10.3892/or.2014.3703
Pages: 1314-1318

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study characterized the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) expression profile in a longitudinal study during melanoma progression, in lesions obtained from the same patients: a primary skin lesion, a lymph node and a distant metastasis. The present study is expected to increase our understanding of the expression patterns of CEACAM1 in melanoma development. We identified 20 patients who could be analyzed for CEACAM1 expression over the course of disease progression. The pathology blocks were cut, and two slides were generated for each specimen. One underwent standard hematoxylin and eosin (H&E) staining and a corresponding slide underwent immunohistochemical staining for the detection of CEACAM1. For 13 patients who were able to be followed up serially from primary lesion, lymph node and distant metastasis, a borderline significant increase in the staining of the membrane was noted (P=0.06). In contrast, there was no equivalent increase in cytoplasmic CEACAM1 in the same group of patients. For the cohort of 20 patients with primary and distant metastasis, a significant increase in the membrane staining was noted (P=0.026) and again, no equivalent significant increase in cytoplasmic staining was observed. We report that CEACAM1 expression increases along the course of disease development and progression of a patient. CEACAM1 represents a novel area of research which may have profound influence in future methods of harnessing cellular immunity to combat this disease. The results of the present study confirm that CEACAM1 is potentially an extremely useful target in arresting melanoma progression.

View Figures

View References

1	Sapoznik S, Hammer O, Ortenberg R, et al: Novel anti-melanoma immunotherapies: Disarming tumor escape mechanisms. Clin Dev Immunol. 2012:8182142012. View Article : Google Scholar : PubMed/NCBI
2	Hodi FS, O’Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
3	Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hamid O, Robert C, Daud A, et al: Safety and tumor response with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
5	Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
6	Ortenberg R, Sapir Y, Raz L, et al: Novel immunotherapy for malignant melanoma with a monoclonal antibody that block CEACAM1 homophillic interactions. Mol Cancer Ther. 6:1300–1310. 2012. View Article : Google Scholar
7	Gray-Owen SD and Blumberg RS: CEACAM1:contact-dependent control of immunity. Nat Rev Immunol. 6:433–446. 2006. View Article : Google Scholar : PubMed/NCBI
8	Dango S, Sienel W, Schreiber M, et al: Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is associated with increased angiogenic potential in non small cell lung cancer. Lung Cancer. 60:426–433. 2008. View Article : Google Scholar : PubMed/NCBI
9	Zhou CJ, Liu B, Zhu KX, et al: The different expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and possible roles in gastric carcinoma. Pathol Res Pract. 205:483–489. 2009. View Article : Google Scholar
10	Ortenberg R, Galore-Haskel G, Greenberg I, et al: CEACAM1 promotes melanoma cell growth through Sox-2. Neoplasia. 16:451–460. 2014. View Article : Google Scholar : PubMed/NCBI
11	Thies A, Moll I, Berger J, et al: CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 20:2530–2536. 2002. View Article : Google Scholar : PubMed/NCBI
12	Laack E, Nikbakht H, Peters A, et al: Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol. 20:4279–4284. 2002. View Article : Google Scholar : PubMed/NCBI
13	Sienel W, Dango S, Woelfle U, et al: Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res. 9:2260–2266. 2003.PubMed/NCBI
14	Muller MM, Klaile E, Vorontsova O, et al: Homophillic adhesion and CEACAM1-S regulate dimerization of CEACAM1-L and recruitment of SHP-2 and c-SRC. J Cell Biol. 187:569–581. 2009. View Article : Google Scholar
15	Chen Z, Chen L, Qiao SW, et al: Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits proximal TCR signaling by targeting ZAP-70. J Immunol. 180:6085–6093. 2008. View Article : Google Scholar : PubMed/NCBI
16	Markel G, Leiberman N, Katz G, et al: CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol. 168:2803–2810. 2002. View Article : Google Scholar : PubMed/NCBI
17	Markel G, Wolf D, Hanna J, Gazit R, et al: Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest. 110:943–953. 2002. View Article : Google Scholar : PubMed/NCBI
18	Markel G, Seidman R, Stern N, et al: Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophillic carcinoembryonic cell adhesion molecules 1 interactions. J Immunol. 177:6062–6071. 2006. View Article : Google Scholar : PubMed/NCBI
19	Markel G, Ortenberg R, Seidman R, et al: Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immmunother. 59:215–230. 2010. View Article : Google Scholar
20	Ebrahimnejad A, Streichert T, Nollau P, et al: CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol. 165:1781–1787. 2004. View Article : Google Scholar : PubMed/NCBI
21	Gamblicher T, Grothe S, Rotterdam S, et al: Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions. Am J Clin Pathol. 131:782–787. 2009. View Article : Google Scholar
22	Markel G, Seidman R, Cohen Y, et al: Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology. 126:186–200. 2009. View Article : Google Scholar :
23	Eggermont AM, Chiarion-Seleni V, Grob JJ, et al: Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. In: Presented at the 2014 Annual Meeting of the American Society of Clinical Oncology; May 30–June 2, 2014; Chicago, IL. J Clin Oncol. 32(15 Suppl): pp. LBA90082014